LeMaitre Vascular (LMAT) Stock Rating Lowered by ValuEngine

ValuEngine cut shares of LeMaitre Vascular (NASDAQ:LMAT) from a hold rating to a sell rating in a research report released on Monday morning.

Other analysts have also recently issued reports about the company. Roth Capital raised LeMaitre Vascular from a neutral rating to a buy rating and lowered their price target for the company from $39.00 to $34.00 in a research note on Monday, October 8th. BidaskClub raised LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday, November 23rd. Zacks Investment Research upgraded LeMaitre Vascular from a hold rating to a buy rating and set a $32.00 price objective for the company in a research report on Tuesday, October 9th. Canaccord Genuity decreased their price objective on LeMaitre Vascular from $40.00 to $32.00 and set a hold rating for the company in a research report on Monday, October 8th. Finally, Lake Street Capital lowered LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, October 5th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of Hold and a consensus price target of $35.86.

Shares of LMAT stock traded down $0.94 on Monday, reaching $22.86. The company had a trading volume of 1,525 shares, compared to its average volume of 122,739. The stock has a market cap of $450.19 million, a PE ratio of 26.30, a price-to-earnings-growth ratio of 2.05 and a beta of 1.15. LeMaitre Vascular has a 12 month low of $21.79 and a 12 month high of $41.28.

In related news, Director Michael H. Thomas sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $27.93, for a total value of $558,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares in the company, valued at approximately $558,600. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 20.30% of the stock is currently owned by insiders.

Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC boosted its position in LeMaitre Vascular by 222.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,451 shares of the medical instruments supplier’s stock worth $149,000 after acquiring an additional 3,072 shares during the last quarter. First Trust Advisors LP acquired a new stake in shares of LeMaitre Vascular in the 3rd quarter valued at approximately $214,000. Jane Street Group LLC acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $206,000. Fifth Third Bancorp boosted its holdings in shares of LeMaitre Vascular by 18,122.2% in the 3rd quarter. Fifth Third Bancorp now owns 8,200 shares of the medical instruments supplier’s stock valued at $318,000 after buying an additional 8,155 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of LeMaitre Vascular in the 2nd quarter valued at approximately $298,000. 81.35% of the stock is owned by hedge funds and other institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: What is a good rate of return for a mutual fund?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply